DAMORA THERAPEUTICS, INC. (DMRA)

Healthcare · Pharmaceuticals · Price $29.00
Updated: Aug 31, 2026
Low Multiple — Healthcare
P/E of 3.87x is below the 18x moderate threshold Zyberno applies to Healthcare businesses — potentially a value opportunity.
P/E Ratio (TTM)
3.87x
Very low P/E - potentially undervalued or facing challenges
Earnings Yield
25.83%
1 / P/E Ratio
EPS (TTM)
$7.49
Diluted Earnings Per Share
Stock Price
$29.00
Current Market Price
PEG Ratio
-999.00
Negative growth - PEG not meaningful

🧮 DMRA P/E Ratio Calculation

P/E Ratio = Stock Price ÷ Earnings Per Share (TTM)
Stock Price $29.00
÷
Earnings Per Share (TTM) $7.49
= P/E Ratio 3.87x

What is the P/E Ratio?

The Price-to-Earnings (P/E) Ratio is one of the most widely used valuation metrics. It tells you how much investors are willing to pay for each dollar of a company's earnings. Zyberno calculates P/E using trailing twelve month (TTM) diluted earnings from official SEC filings.

P/E Ratio = Stock Price ÷ Earnings Per Share (TTM)
Using diluted EPS which accounts for stock options and convertible securities

How to Interpret the P/E Ratio

Low P/E (Under 15x)

May indicate undervaluation, or the market expects declining earnings. Common in mature, slow-growth industries.

Average P/E (15-20x)

Roughly in line with historical S&P 500 average. Suggests fairly valued with moderate growth expectations.

High P/E (20-35x)

Investors expect above-average earnings growth. Common for technology companies and market leaders.

Very High P/E (35x+)

Extreme growth expectations priced in. Significant valuation risk if growth slows.

PEG Ratio: P/E Adjusted for Growth

The PEG Ratio addresses a key limitation of P/E by factoring in earnings growth. A PEG of 1.0 suggests fair value; below 1.0 may indicate undervaluation, while above 2.0 suggests a premium price for growth.

PEG Ratio = P/E Ratio ÷ Earnings Growth Rate
DMRA: 3.87x ÷ N/A = -999.00

P/E Ratio Limitations

The P/E ratio doesn't work for companies with negative earnings. It can be manipulated by one-time charges or gains, and it doesn't account for debt levels or growth rates. Use P/E alongside PEG ratio, EV/EBITDA, and Owner Earnings yield for a complete picture.

Comparing Valuation Metrics

EPS: $7.49 →

The denominator in the P/E calculation. Represents profit allocated to each outstanding share.

Price-to-Book: N/A

Compares stock price to book value. Useful for asset-heavy industries like banking and manufacturing.

EV/EBITDA: N/A

Accounts for debt and is useful for comparing companies with different capital structures.

Owner Earnings Yield →

Warren Buffett's preferred metric. Shows cash return to owners as a percentage of market cap.

📊 Full DMRA Stock Report

Intrinsic value, margin of safety, DCF valuation, and 250+ metrics.

📈 DMRA Earnings Per Share

Deep dive into EPS trends, quarterly history, and earnings growth analysis.

🏆 DMRA ROIC

Measure capital efficiency — how well management deploys every dollar invested.

💎 DMRA Intrinsic Value

Calculate what DMRA is truly worth using DCF and Owner Earnings models.

💵 DMRA Owner Earnings

Warren Buffett's preferred measure of true earning power and cash generation.

🛡️ DMRA Margin of Safety

See if DMRA is trading below its intrinsic value.

View Full DMRA Report Find More Quality Stocks
📊 Valuation Trilogy
Three interconnected metrics built on Owner Earnings
💎
Intrinsic Value
DCF Fair Value
🛡️
Margin of Safety
Valuation Gap
🎯
Expected Return
Projected Annual
Click any metric for full methodology and detailed analysis

Summary: DMRA P/E Ratio

DAMORA THERAPEUTICS, INC. (DMRA) trades at a P/E of 3.87x, which Zyberno classifies as a low multiple for a Healthcare company — below the 18x level Zyberno considers moderate for healthcare companies where pipeline value and patent protection justify premium multiples. Earnings yield: 25.83%. May indicate a value opportunity or reflect market concerns about future earnings.

Based on 0 quarters of SEC filings, DMRA's EPS is currently $7.49 on a trailing twelve-month basis. Zyberno cross-references the P/E ratio with business quality — a high multiple on a high-quality business (strong ROE, ROIC, and FCF) carries less risk than the same multiple on a weaker business. For complete financial analysis, view the full DMRA stock report on Zyberno.

Frequently Asked Questions

What is DMRA's current P/E Ratio?

DAMORA THERAPEUTICS, INC.'s trailing twelve month (TTM) P/E Ratio is 3.87x, within the context of Healthcare sector multiples where Zyberno considers 18–28x moderate. Investors are paying $3.87 for every $1 of annual earnings.

Is DMRA's P/E Ratio high or low?

DAMORA THERAPEUTICS, INC. (DMRA) trades at a P/E of 3.87x, which Zyberno classifies as a low multiple for a Healthcare company — below the 18x level Zyberno considers moderate for healthcare companies where pipeline value and patent protection justify premium multiples. Earnings yield: 25.83%. May indicate a value opportunity or reflect market concerns about future earnings.

What is DMRA's earnings yield?

DMRA's earnings yield is 25.83%, which is the inverse of the P/E ratio (1 ÷ P/E). This represents the theoretical return if all earnings were distributed to shareholders.

How is P/E Ratio calculated?

P/E Ratio = Stock Price ÷ EPS. For DMRA: $29.00 ÷ $7.49 = 3.87x.

What is DMRA's PEG Ratio?

DMRA's PEG Ratio is -999.00. Negative growth - PEG not meaningful. PEG below 1.0 is often considered undervalued, while above 2.0 may indicate overvaluation relative to growth.

📊 Full DMRA Stock Report

See DMRA's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.

🏆 DMRA ROIC

Compare to Return on Invested Capital — the most comprehensive measure of capital efficiency.

📈 DMRA ROE

Compare to Return on Equity and understand the impact of leverage on returns.

🎯 DMRA Earnings Surprise (SUE)

See whether DMRA is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.

👤 DMRA Owner Earnings

Warren Buffett's preferred measure of true economic earnings available to owners.

💰 DMRA Net Income

See the bottom-line profit that drives return calculations.

📊 DMRA EPS

Earnings per share — net income on a per-share basis.

View Full DMRA Report Find More Quality Stocks
Scroll to Top